Sobrevida global de los pacientes con carcinoma hepatocelular que recibieron embolización hepática transarterial en el Hospital México durante el periodo 2014 al 2019
Guardado en:
| Autor: | |
|---|---|
| Formato: | tesis |
| Fecha de Publicación: | 2019 |
| Descripción: | Hepatocellular carcinomais a frequent liver neoplasm in patients with cirrhotic disease. The only curativetherapies available are liver resection or transplantation. Unfortunately, less than 5% present with these characteristics at the time of diagnosis.Regional therapies such as ablation of the tumor lesion with radiofrequency or transarterial embolizationwith or without chemotherapy are the most commonly used in patients with irresectablehepatocarcinoma. These therapies increase survival compared to systemic therapy.The objective of the study is to describe the overall survival of patients with hepatocarcinoma who underwent transarterial embolization at Hospital México since 2014. In addition, make a comparison of survival by age, intention to treat, liver function and chemotherapy used.It is a retrospective, descriptive, cohort study. Seventy-one patientswho met the inclusion and exclusion criteria were included. Overall survival (time in months from the procedure to the date of death or data review) in patients with hepatocarcinoma who underwent transarterial embolization was calculated.The median overall survival of patients with hepatocarcinoma who underwent chemoembolization was 19.1 months,comparable to that reported worldwide. There was a statistically significant increase in survival in patients who underwent chemoembolization with epirubicin compared with cisplatin and in those patients undergoing transarterial embolization (chemoembolization or bland embolization) who intended curative treatment compared with palliative intent. |
| País: | Kérwá |
| Institución: | Universidad de Costa Rica |
| Repositorio: | Kérwá |
| OAI Identifier: | oai:kerwa.ucr.ac.cr:10669/80175 |
| Acceso en línea: | https://hdl.handle.net/10669/80175 |
| Palabra clave: | cáncer |